Keywords:
Pub Date:
From
Month
January February March April May June July August September October November December
Year
2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997
To
Month
January February March April May June July August September October November December
Year
2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997
Lilly Halts IDENTITY Trials as Patients Worsen on Secretase Inhibitor
Anti-Aβ Oligomer Headed for Phase 3 Clinical Trial
Research Brief: Lithium for ALS—Another Nail in the Coffin?
Drugs, Old and New, Offer Glimmer of Hope for Huntington’s
Paper Alert: Lithium for ALS Deemed Futile, Study Stops Early
Research Brief: Medivation Scales Back
Dimebon Disappoints in Phase 3 Trial
Dimebon for HD—A Hint of Cognitive Benefit?
Clinical Trials for ALS: Taking Stock of 2009, Looking to 2010
Drug Brief: Generic Aricept Approval—Melts in Your Mouth?
Paper Alert—Phase 3 Tarenflurbil Data Published
Drug Brief—Adverse Events Prompt Dose Drop in Elan Trial
Paper Alert-cum-SfN: Bapineuzumab Published, More AN1792 Presented
Research Brief: Glatiramer Slows Progression From High Risk to MS
Medical Foods—Food for Thought, But Think Twice
Dimebon: Bright Star or Black Hole?
Medical Foods—Fallback Option for Elusive AD Drug Status?
Vienna: New Shoot Among Ashes of Drug Trials
NO Joke: Viagra Lessens Aβ, Cognitive Problems in AD Mice
News Brief: What’s Up With Iplex?
Drug News Brief: Bapineuzumap Trial Drops Highest Dose
Antipsychotics on Trial Again—DART-AD Confirms Increased Mortality
IGF-1 Disappoints in Trials for AD, ALS
Big Ginkgo Prevention Trial Comes Up Negative
Experts Slam Marketing of Tramiprosate (Alzhemed) as Nutraceutical
Home
Join us on Tuesday, 14 September 2010 at noon, U.S. Eastern Daylight Saving Time, for a Webinar, 
